We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Finds AbbVie’s Atopic Dermatitis Treatment Rinvoq Too Expensive
ICER Finds AbbVie’s Atopic Dermatitis Treatment Rinvoq Too Expensive
The Institute for Clinical and Economic Review (ICER) has determined that AbbVie’s Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor being developed to treat atopic dermatitis, is not a cost-effective treatment for the disease.